Figure 1: Monoclonal antibodies cetuximab, panitumumab, and nimotuzumab; tyrosine-kinase inhibitor serlotinib and gefitinib; and EGF and HER-1 cancer vaccines are target treatments that produce inhibition of signal transduction.